EMA Authorised: Ferriprox (Deferiprone) — Chiesi Farmaceutici S.p.A.

View source ↗

Summary

The European Medicines Agency authorised Ferriprox (deferiprone) from Chiesi Farmaceutici S.p.A. for the treatment of beta-thalassemia and iron overload.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• FERRIPROX (deferiprone)

Snippet

Status: Authorised. Therapeutic area: beta-Thalassemia;Iron Overload. MAH: Chiesi Farmaceutici S.p.A.. Decision date: 20/04/2026